Back to Home

Sitemap

Archive History

main-img

Back to Home » June 2021 News » EHA:Eficacia de la vacuna Pfizer/BioNTech BNT162b2 en pacientes que reciben CAR-T

EHA:Eficacia de la vacuna Pfizer/BioNTech BNT162b2 en pacientes que reciben CAR-T

June 12, 2021

- European Hematology Association:La respuesta humoral a la vacuna Pfizer/BioNTech BNT162b2 se ve afectada en pacientes que reciben CAR-T o terapia inmunosupresora de alta intensidad LA HAYA, Países Bajos, 12 de junio de 2021 /PRNewswire/ -- La vacuna Pfizer/BioNTech BNT162b2 ha sido...

Source URL: https://www.prnewswire.com:443/news-releases/eha-eficacia-de-la-vacuna-pfizer-biontech-bnt162b2-en-pacientes-que-reciben-car-t-868759422.html

Browse News

Risen Energy Unveils NewT@N at SNEC 2021, the Industry's First Mass-Produced 700W High-Efficiency Power Module

European Hematology Association: Overall Survival Benefit Established With Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) in Elderly Patients with Transplant-ineligible Newly Diagnosed Multiple Myeloma (NDMM): Long-Term Interim Analysis of the MAIA Study

European Hematology Association: Humoral Response to the Pfizer/BioNTech BNT162b2 Vaccine Is Impaired in Patients Receiving CAR-T or High-Intensity Immunosuppressive Therapy